Indication
Non-small-cell Lung Cancer
14 clinical trials
22 products
1 drug
Product
PembrolizumabClinical trial
Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-04-10
Product
CisplatinProduct
SAR408701Product
PemetrexedProduct
CarboplatinProduct
TJ271Clinical trial
A Multi-center, Open-label Phase II Clinical Trial of TJ271 Injection in Combination With Pembrolizumab in Chinese Patients With Advanced Solid TumorsStatus: Withdrawn, Estimated PCD: 2023-12-31
Clinical trial
A Single-arm, Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HL-085 Capsules Combined With Vemurafenib in the Treatment of BRAF V600E Mutated Patients With Unresectable Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Status: Not yet recruiting, Estimated PCD: 2025-09-24
Product
PF-07820435Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORSStatus: Recruiting, Estimated PCD: 2027-01-31
Product
SasanlimabProduct
HL-085+VemurafenibProduct
BotensilimabProduct
BalstilimabClinical trial
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced CancerStatus: Recruiting, Estimated PCD: 2026-12-01
Product
SintilimabClinical trial
An Open Label, Multicenter, Phase Ib Study Evaluating IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Advanced, Recurrent or Metastatic Non-small-cell Lung Cancer (NSCLC)Status: Completed, Estimated PCD: 2022-07-31
Clinical trial
A Study of the Safety and Efficacy of QL1706 in Combination With Chemotherapy in First-Line Treatment of Patients With Stage IIIB/C and Stage IV Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-01-01
Product
QL1706Product
IBI310Product
PF-07209960Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORSStatus: Terminated, Estimated PCD: 2023-05-03
Clinical trial
An Open-label,Multi-center, -Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Antitumor Activity of GH21 in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-31
Product
GH21Clinical trial
A Single-arm, Phase II Study of Preoperative Gefitinib for Stage II-IIIa NSCLC With Activating EGFR MutationStatus: Completed, Estimated PCD: 2015-10-01
Product
GefitinibClinical trial
Randomized, Double-blind, Parallel Controlled, Multicenter Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Arotinib Capsules and Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer After Immune ResistanceStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
An Explorative Study on Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable Non-small-cell Lung CarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-11-01
Product
camrelizumabClinical trial
A Phase 1b/2 Open-Label Study to Evaluate Pharmacokinetics, Safety, Efficacy, and Pharmacodynamics of PF-06801591 (PD-1 Inhibitor) in Participants With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2022-03-03
Product
PF-06801591Clinical trial
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Newly Diagnosed Stage Ⅲ Unresectable Non-small Cell Lung Cancer: a Open-label, Single-arm Prospective Clinical TrialStatus: Recruiting, Estimated PCD: 2024-12-31